<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209492</url>
  </required_header>
  <id_info>
    <org_study_id>Leuprorelin-5002</org_study_id>
    <secondary_id>JapicCTI-163213</secondary_id>
    <nct_id>NCT03209492</nct_id>
  </id_info>
  <brief_title>Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for &quot;Prostate Cancer&quot;</brief_title>
  <official_title>Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for &quot;Prostate Cancer&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety in patients with prostate cancer
      receiving the drug in the routine clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called Leuprorelin acetate (Leuplin PRO for Injection
      Kit 22.5 mg). Leuprorelin acetate is being tested to treat people who have prostate cancer.

      This study will look at the safety in patients with prostate cancer receiving the drug in the
      routine clinical setting.

      The study will enroll approximately 300 patients.

      â€¢ Leuprorelin acetate

      This multi-center trial will be conducted in Japan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who had one or more adverse events</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Time frame is defined the duration from the start of treatment with Leuprorelin acetate injection up to 24 weeks after the start of treatment (or at the time the observation is discontinued).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who had one or more adverse drug reactions</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Adverse drug reaction refers to adverse events related to administered drug. Time frame is defined the duration from the start of treatment with Leuprorelin acetate injection up to 24 weeks after the start of treatment (or at the time the observation is discontinued).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Leuprorelin acetate</arm_group_label>
    <description>Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin acetate</intervention_name>
    <description>Leuplin PRO for Injection Kit 22.5 mg</description>
    <arm_group_label>Leuprorelin acetate</arm_group_label>
    <other_name>Leuplin PRO for Injection Kit 22.5 mg</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of participants with a diagnosis of prostate cancer and
        received dose of Leuplin PRO for Injection Kit 22.5 mg/Leuprorelin acetate in the routine
        medical care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with prostate cancer will be included.

        Exclusion Criteria:

          -  Participants with previous history of hypersensitivity to any of the ingredients of
             the drug or synthetic LH-RH or LH-RH derivatives
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takeda Selected Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

